Careprost 3ml Eye Drops

Careprost is a 3 mL bottle of bimatoprost 0.03% eye drops made in India by Sun Pharma for glaucoma. People buy it for their eyelashes because bimatoprost at the same 0.03% strength is the active ingredient in Latisse, the FDA-approved treatment for thin or short lashes. We sell Careprost for $9 a bottle.

This page covers the price, how to apply it to your lashes following the Latisse method as closely as possible, what the trials found about results and side effects, who should not use it, and how delivery works. Clinical figures come from the US prescribing information for Latisse and the studies listed at the end.

Careprost at a glance

Price

Careprost costs $9 per 3 mL bottle (September 2026; the price above always shows the current figure). Shipping is a flat $25 on orders under $149, so it is cheaper per bottle to order several at once or combine Careprost with other items. The Latisse 3 mL pack is sized for 35 nights on both upper lids; at a similar rate, 16 weeks would take about 3 to 4 bottles.

The Latisse and generic figures are what US pharmacies paid for 3 mL in September 2026 according to the Medicaid NADAC survey; the price at the counter is higher, and Latisse is usually not covered by insurance because it is a cosmetic treatment. Our Latisse cost guide has more detail.

Careprost, Latisse and Lumigan

All three contain bimatoprost. Latisse (Allergan, now AbbVie) was approved by the FDA on 24 December 2008 for hypotrichosis of the eyelashes. Lumigan is Allergan's bimatoprost glaucoma drop; the US version is now 0.01%, and 0.03% is still sold in some countries. Careprost is Sun Pharma's 0.03% glaucoma drop, the same strength as Latisse. It was not the product used in the Latisse trials; what it shares is the active ingredient and its strength, which is why following the Latisse method as closely as possible is the nearest you can get to the conditions behind the published results. See Lumigan vs Careprost and Careprost vs Latisse.

Careprost Plus is a different product: bimatoprost with timolol, a beta blocker, for glaucoma only. It is not a lash product, and timolol is unsuitable for people with asthma, severe COPD, a slow heart rate or certain heart conditions.

How to apply Careprost to your lashes

1. At night, wash your face, remove all makeup and take out contact lenses. Lenses can go back in 15 minutes after applying.
2. Put one drop of Careprost on a sterile single-use applicator, just behind the tip. Do not let the bottle nozzle touch anything.
3. Draw the applicator along the base of the upper lashes, from the inner corner to the outer corner. The lid should feel lightly moist, not wet.
4. Blot any solution that spreads beyond the lash line with a tissue.
5. Throw the applicator away and use a new one for the other eye.

Do not apply it to the lower lash line, and do not use more than one drop per eye or apply it more than once a day: the label says extra applications do not increase growth, and runoff can darken skin or grow hair where it lands. If you miss a night, just apply as usual the next evening. Our step by step Careprost application guide explains the reason behind each rule.

How long until you see results

In the 278-patient trial behind the Latisse approval, only 15% of people on bimatoprost had a visible improvement at week 4, against 8% on the inactive vehicle solution. By week 8 it was 50% against 15%, and by week 16, 78% against 18%.

At week 16, average lash length rose by 25% (1.4 mm) against 2% on vehicle, fullness by 106% against 12%, and darkness by 18% against 3%. These are averages; some people see more and some see little.

What happens when you stop

The change is not permanent. The Latisse label says lashes are expected to return to their previous state after treatment stops. In a 12-month trial, results held for about 2 months after stopping and had largely faded 4 to 6 months later: 78% still had at least a 1-grade improvement two months after stopping, 47% at four months and 35% at six months. Our Careprost results week by week guide covers keeping results over time.

Side effects

In the 4-month Latisse trial, the most common side effects were itchy eyes, red eyes, skin darkening, eye irritation, dry eye symptoms and redness around the eye, each in under 4% of patients. In a 12-month trial of 118 people with naturally sparse lashes, red eyes were reported by 8.5%, itchy eyelids by 5.9% and red eyelids by 5.1%. The label also warns about:

• Brown darkening of the iris, which is likely to be permanent.
• Darkening of the eyelid skin, reversible after stopping in most people.
• Hair growth outside the lash line wherever the solution repeatedly touches skin.
• Infection from reused applicators or a contaminated bottle tip.
• Uneven lashes between the eyes in length, thickness, colour, number or direction, usually reversible after stopping.

Since approval there have also been reports of fat loss around the eye that deepens the lid crease or causes a drooping lid, temporary lash loss, and eyelid swelling. Our bimatoprost safety guide covers these in more depth.

Who should not use Careprost

• Anyone allergic to bimatoprost or any ingredient, including the preservative benzalkonium chloride. This is a contraindication in the label.
• Anyone using glaucoma or eye pressure drops, or with a history of abnormal eye pressure, except under close supervision of their eye doctor with eye pressure checks. With prostaglandin drops such as Lumigan or latanoprost, extra bimatoprost can blunt the pressure-lowering effect.
• Anyone with active inflammation inside the eye such as uveitis, or at risk of macular oedema.
• Anyone pregnant or breastfeeding: there are no adequate studies, and the label says to use it in pregnancy only if the benefit justifies the risk.

Stop and see a doctor for eye pain, discharge, persistent redness, eyelid swelling, a rash or other signs of an allergic reaction around the eye, a change in iris colour or any change in vision, and before any eye surgery. Tell whoever checks your eye pressure that you use bimatoprost on your lashes.

Prescription and legal status

Bimatoprost is a prescription medicine in the US, UK, Australia and Canada. Careprost is not licensed by the FDA, the MHRA, the TGA or Health Canada, and in the US the FDA says personal importation of unapproved medicines is illegal in most circumstances. See Is Careprost legal in the USA? We recommend seeing a doctor or optometrist before you start, especially if you have any eye condition.

Storage and checking your bottle

The Latisse label says to store bimatoprost between 2°C and 25°C; keep the cap on between uses and never let the nozzle touch anything. Follow any discard-after-opening period printed on your Careprost pack. When your order arrives, check that the carton names Sun Pharma and shows the strength, a batch number and an expiry date. These checks cannot prove a bottle is genuine on their own, because counterfeiters copy packaging. If a bottle causes unusual symptoms, stop using it, seek medical advice, and report it to your medicines regulator (the MHRA Yellow Card scheme in the UK, FDA MedWatch in the US, the TGA in Australia or Health Canada) as well as to us.

Delivery

We ship Careprost to the US, UK, Australia and Canada in plain packaging with tracking. Standard delivery takes 7 to 14 business days to most countries. Bimatoprost does not need a cold chain. Shipping costs a flat $25 on orders under $149 and is free from $149. See our shipping page for times by region.

Related guides and products

• How to apply Careprost to your eyelashes
• Careprost results week by week
• Careprost vs Latisse
• Lumigan vs Careprost
• Bimatoprost for eyebrows

Other bimatoprost 0.03% products we stock: Latisse Generic 0.03% and Lashisma. These are also made in India and are not FDA-approved products.

Sources

• LATISSE (bimatoprost ophthalmic solution) 0.03%, US prescribing information and patient information, sections 2, 4, 5, 6, 8, 14, 16 and 17. DailyMed
• Drugs@FDA: LATISSE, NDA 022369, approved 24 December 2008.
• Glaser DA et al. Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol 2015;172(5):1384-94. PMID 25296533.
• Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC), 2026 file, as of 23 September 2026. data.medicaid.gov
• GANFORT (bimatoprost/timolol) EPAR product information, section 4.3. European Medicines Agency.
• US Food and Drug Administration. Personal Importation. FDA

This page is for information and is not medical advice. Bimatoprost is a prescription medicine; talk to a doctor, optometrist or pharmacist before using it.